Hussman Strategic Advisors Inc. Invests $2.69 Million in Humana Inc. $HUM

Hussman Strategic Advisors Inc. bought a new position in shares of Humana Inc. (NYSE:HUM) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,500 shares of the insurance provider’s stock, valued at approximately $2,689,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CoreCap Advisors LLC grew its position in Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares during the period. Rosenberg Matthew Hamilton grew its position in Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after buying an additional 68 shares during the period. Mather Group LLC. acquired a new position in Humana during the third quarter worth about $34,000. Larson Financial Group LLC grew its position in Humana by 114.1% during the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after buying an additional 81 shares during the period. Finally, Fulcrum Asset Management LLP acquired a new position in Humana during the third quarter worth about $42,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

NYSE:HUM opened at $233.87 on Friday. The company has a quick ratio of 2.00, a current ratio of 1.77 and a debt-to-equity ratio of 0.66. The company has a market cap of $28.08 billion, a P/E ratio of 25.01, a P/E/G ratio of 2.50 and a beta of 0.67. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $315.35. The firm’s 50 day moving average is $188.41 and its two-hundred day moving average is $227.22.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. The company had revenue of $39.65 billion for the quarter, compared to the consensus estimate of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. Humana’s revenue was up 23.5% on a year-over-year basis. During the same quarter last year, the firm posted $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. Analysts expect that Humana Inc. will post 9.06 EPS for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.5%. Humana’s dividend payout ratio (DPR) is currently 37.86%.

Insider Activity at Humana

In other news, insider Sanjay K. Shetty acquired 810 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were bought at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the acquisition, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. This trade represents a 7.47% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have weighed in on HUM shares. Wells Fargo & Company upped their target price on shares of Humana from $206.00 to $227.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 7th. Truist Financial upped their target price on shares of Humana from $220.00 to $270.00 and gave the stock a “hold” rating in a research report on Thursday. Morgan Stanley set a $146.00 target price on shares of Humana in a research report on Thursday, February 12th. The Goldman Sachs Group upped their target price on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a research report on Thursday. Finally, Mizuho upped their target price on shares of Humana from $258.00 to $290.00 in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $247.61.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Multiple brokers lifted price targets sharply (Jefferies, Mizuho, Cantor, Evercore, Truist, Leerink, Deutsche Bank), signaling renewed upside expectations and analyst confidence after the quarter. Jefferies PT to $290 Mizuho PT to $290 Cantor PT to $264
• Positive Sentiment: Company aims for at least a 3% Medicare Advantage margin by 2028 while preparing 2027 bids and integrating MaxHealth — a clear operational target that can support future margin recovery. MA margin target article
• Positive Sentiment: Deutsche Bank and other shops issued constructive commentary/forecasts supporting the stock after Q1, reinforcing buy-side interest. Deutsche Bank positive forecast
• Neutral Sentiment: Sector context: Humana was one of the top performers in April (≈+36%), nearly neck-and-neck with UnitedHealth; market rotation and sector momentum are lifting valuation comparisons. April returns piece
• Neutral Sentiment: Analyst consensus remains around “Hold”/”Market Perform” despite PT changes, so expectations are mixed rather than uniformly bullish. Consensus Hold report
• Negative Sentiment: Goldman raised its target to $195 but kept a sell rating — signaling conviction that the current price is rich versus fundamentals and creating downside pressure. Goldman sell rating
• Negative Sentiment: JPMorgan raised its target to $214 but kept a neutral rating — the PT implies downside from current levels and highlights lingering skepticism about sustainability of margins. JPMorgan PT to $214
• Negative Sentiment: Despite beating Q1 estimates, Humana warned Medicare payments may not keep pace with costs and reported a decline in Medicare Advantage Star ratings; those operational/framing issues are cited by multiple outlets as reasons the stock is under pressure. Q1 beat but Star ratings concern Bloomberg Law

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.